Project Grant K99HL183745
- The National Heart, Lung and Blood Institute awarded Cincinnati Children's Hospital Medical Center $3.193 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to non-invasively quantify alveolar remodeling in cystic fibrosis lung disease using hyperpolarized xenon MRI. The research aims to establish the prevalence and short-term trajectories of emphysema-like remodeling in people with cystic fibrosis receiving CFTR modulator therapy. Cincinnati Children's...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $361,125 on April 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLUME, a human fetal lung multiomics cell atlas with computational models to predict fetal origins and molecular perturbations in childhood interstitial lung diseases (CHILD). The project performs secondary analysis of existing fetal lung and CHILD datasets, leveraging high-resolution spatial...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital $930,637 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to conduct PROSPER (Pulmonary Recovery and Outcomes After Severe Pediatric Respiratory Illness), a multicenter prospective longitudinal cohort study examining how impaired pulmonary function contributes to physical and health-related quality-of-life morbidity among children surviving acute respiratory failure. The...
- The National Heart, Lung, and Blood Institute awarded Wayne State University $756,148 under CFDA 93.837 (Cardiovascular Diseases Research) on July 1, 2026, to develop next-generation enabling technologies for ultrafast functional pulmonary MRI using hyperpolarized xenon-129 gas imaging. The award funds research to advance MRI of hyperpolarized xenon-129 gas, which enables three-dimensional imaging of lung function and reports on regional lung ventilation, diffusion, and gas exchange. Current...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $126,518 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to build a patient-oriented research mentoring program in human neonatal and infant airway biology. The award funds mentoring and research addressing mechanisms regulating airway epithelial immune responses in early life, with particular focus on populations historically excluded from respiratory research: infants with...
The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $331,340 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate dynamic free-breathing 129Xe MRI as a non-invasive functional lung imaging tool for pediatric populations including neonates, infants, toddlers, and young children. The project addresses limitations of current clinical assessment methods for pediatric lung diseases such as bronchopulmonary dysplasia, which affects up to 15,000 infants annually in the U.S. Traditional spirometry is unsuitable for young children due to cooperation requirements, while computed tomography provides structural but not functional information and poses radiation risks. Existing functional lung MRI methods including phase-resolved functional lung (PREFUL) are limited in sensitivity, and breath-hold 129Xe MRI is impractical in infants and toddlers. The award funds development and optimization of free-breathing 129Xe MRI protocols to measure regional ventilation under natural physiological conditions, eliminating breath-holding requirements and extending feasibility to the most vulnerable populations. Validation will occur against established clinical tools including proton ultrashort echo time MRI and impulse oscillometry. Performance of work takes place in Cincinnati, Ohio, with a period of performance from September 1, 2026, through May 31, 2028. The award is classified as a Project Grant, a standard assistance type under the NHLBI research portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/28/26 | ||
| Not listed | $165.7k | 8/10/26 |